Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Accumulated Expenses for 6 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 46.15% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 46.15% decrease, with the full-year FY2024 number at $2.7 million, up 18.59% from a year prior.
  • Accumulated Expenses was $1.2 million for Q3 2025 at Inhibikase Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.7 million in Q4 2024 to a low of $421734.0 in Q4 2021.
  • A 5-year average of $1.6 million and a median of $1.5 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 468.71% in 2022, then plummeted 50.32% in 2024.
  • Inhibikase Therapeutics' Accumulated Expenses stood at $421734.0 in 2021, then surged by 468.71% to $2.4 million in 2022, then fell by 5.77% to $2.3 million in 2023, then grew by 18.59% to $2.7 million in 2024, then tumbled by 56.57% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Accumulated Expenses are $1.2 million (Q3 2025), $2.7 million (Q4 2024), and $2.2 million (Q3 2024).